Recommendations from the national multiple sclerosis society clinical outcomes assessment task force

Annals of Neurology

Volumn 42, Issue 3, 1997, Pages 379-382

  Rudick, Richard ^a   Antel, Jack ^b   Confavreux, Christian ^c   Cutter, Gary ^d   Ellison, George ^e   Fischer, Jill ^f   Lublin, Fred ^g   Miller, Aaron ^h   Petkau, John ⁱ   Rao, Stephen ^j   Reingold, Stephen ^k   Syndulko, Karl ^l   Thompson, Alan ^m   Wallenberg, Joy ⁿ   Weinshenker, Brian ^o   Willoughby, Ernest ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c Hopital De L Anriquaille   (France)

^d UNIVERSITY OF COLORADO   (United States)

^e UCLA MEDICAL CENTER   (United States)

^f DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g MAIMONIDES MEDICAL CENTER   (United States)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ MEDICAL COLLEGE OF WISCONSIN   (United States)

^j National Multiple Sclerosis Society   (United States)

^k VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m BAYER AG   (Germany)

ⁿ MAYO CLINIC   (United States)

^o AUCKLAND CITY HOSPITAL   (New Zealand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; HUMAN; MULTIPLE SCLEROSIS; PRACTICE GUIDELINE; STANDARD;

CLINICAL TRIALS; HUMANS; MULTIPLE SCLEROSIS;

EID: 0031226430     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410420318     Document Type: Article

References (15)

1. Whitaker JN, McFarland HF, Rudge P, et al. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995:1:37-47
2. Rudick R, Antel J, Confavreux C, et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996:40:469-479
3. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983:33: 1444-1452
4. Sipe JC, Knobier RL, Braheny SL, et al. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984;34: 1368-1372
5. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983:308:173180
6. Syndulko K, Ke D, Ellison GW, et al. Comparative evaluations of neuroperformance and clinical outcome assessments in multiple sclerosis. I. Primary dimensions, construct validation and sensitivity to disease progression. Multiple Sclerosis 1996;2: 142-156
7. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehab 1988;69:850-854
8. Gromvall DMA. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills 1977:44:367373
9. Benton AL, Hamsher K. Multilingual aphasia examination. Iowa City, LA: University of Iowa, 1976
10. Smith A. Symbol-digit modalities test: Manual. Los Angeles: Western Psychological Services, 1973
11. Goldsmith CH, Smythe HA, Helewa A." Interpretation and power of a pooled index. J Rheumatol 1993:20:575-578
12. Ellison GW, Myers LW, Mickey MR, et al. A placebocontrolled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 1989:39:1018-1026
13. The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990:27:591-605
14. Goodkin DE, Rudick RA, Medendorp SV, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995:37: 30-40
15. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol 1996:39:285-294